Download a useful infographic to use Twitter around health-related events effectively:
1. Remember, they’re following YOU 2. Be their ears and eyes too 3. Use the event hashtag 4. Be original 5. No time like the present 6. Quote of the day… 7. A picture, a thousand words etc 8. Be a Twitter advocate
UK meds regulator destroys detailed information on the benefits and harms of drugs it has approved after it has held it for 15 years on file
BRITAIN’S medicines regulator has destroyed the original scientific data supporting the licensing of Prozac, the antidepressant drug that is provoking growing controversy over evidence that it is linked to suicide.
It means that scientists who have tried to re-examine the evidence justifying its release may now never be able to find out how good the science was. Patients making compensation claims will face the same problem.
The UK medicines regulator destroys detailed information on the benefits and harms of medicines it has approved after it has held it for 15 years. This means that for medicines which have been on the market for longer than 15 years, which is the majority of them, the Medicines and Healthcare Products Regulatory Agency (MHRA) no longer holds the data it based its licensing decision on.
This came to light after Professor Peter Gotzsche, co-founder of the Cochrane Collaboration, asked the European Medicines Agency for the data used to support the licensing of the antidepressant Prozac (fluoxetine). Gotzsche was referred to the MHRA as the UK is designated as the Reference Member State for Prozac meaning the MHRA is the nominated body within the EU that holds the information on the drug. Never the less, the MHRA had shredded clinical evidence about the benefits and harms of the product. It told Professor Gotzsche “Under MHRA record management policy, all application files and data for licences are held for 15 years. After this period, files are destroyed unless there is a legal, regulatory, or business need to keep them, or unless they are considered to be of lasting historic interest.”
The Sunday Times reported yesterday that “the MHRA said it had shredded the detailed information and held only some documents that summarised the findings. Eli Lilly, the manufacturer, retains the data and the MHRA said it can order it to be submitted.”
Professor Gotzsche wrote in a letter in the BMJ in June 2011 “As citizens in the EU, we should not accept this state of affairs. … The UK government should introduce legislation that will prevent the MHRA in future from destroying the evidence in its possession.”
Dr Ben Goldacre, co-founder of AllTrials said: “The MHRA needs to recognise that the world has changed, it is no longer acceptable for decisions about medicines to be based on secret meetings, about secret information that is then shredded. Doctors, researchers and patients need access to all the evidence, to make fully informed decisions about which treatment is best, and help spot problems with treatments as quickly as possible. Science progresses, and medicine improves, when we have many eyes on the data.”
MHRA shreds clinical trial info after 15 years, AllTrials.net, News release, 24th March 2014
More information, letters, opinions and articles:
Drug regulator destroys Prozac research, TheSundayTimes, 23 March 2014
BPA oral prenatal exposure increases mammary cancer susceptibility in offspring
Background Bisphenol-A (BPA) is a ubiquitous environmental chemical with reported endocrine-disrupting properties.
Our goal in this study was to determine whether prenatal exposure to BPA predisposes the adult rat mammary gland to carcinogenesis.
Pregnant rats were treated orally with 0, 25, or 250 μg BPA/kg body weight (BW) from gestation day (GD) 10 to GD21. For tumorigenesis experiments, prenatally exposed female offspring received a single gavage of 7,12-dimethylbenz(a)anthracene (DMBA; 30 mg/kg BW) on postnatal day (PND) 50, or PND100.
Prenatal exposure of the dam to 250 μg BPA/kg BW combined with a single exposure of female offspring to DMBA on PND100, but not on PND50, significantly increased tumor incidence while decreasing tumor latency compared with the control group. Prenatal exposure of the dam to 250 μg BPA/kg BW, in the absence of DMBA to the female offspring, increased cell proliferation and elicited differential effects at the protein level at PND100 compared with PND50. Differentially regulated proteins in the mammary gland included estrogen receptor-α, progesterone receptor-A, Bcl-2, steroid receptor coactivators, epidermal growth factor receptor, phospho-insulin-like growth factor 1 receptor, and phospho-Raf.
Our study demonstrates that oral prenatal exposure to BPA increases mammary cancer susceptibility in offspring and shifts the window of susceptibility for DMBA-induced tumorigenesis in the rat mammary gland from PND50 to PND100. These changes are accompanied by differential effects of prenatal BPA exposure on the expression of key proteins involved in cell proliferation.
Laëtitia POISSON-DELEGLISE Présidente de MAIA & Déborah SCHOUHMANN-ANTONIO, Thérapeute en Périnatalité, sont très heureuses de vous faire part de cet événement :
Communiqué de presse :
” Rendez-vous le 23 mai 2014 à l’Institut PASTEUR à Paris : L’association MAIA et FAMILI organisent la 1ère Journée Nationale de l’Infertilité en présence de professionnels de santé, premier forum en direct d’informations et d’aide aux personnes infertiles. Une journée pour parler sans tabou de l’infertilité, répondre aux questions des personnes infertiles et leur entourage, et récolter des fonds pour la recherche médicale. Parce que l’infertilité est encore une souffrance le plus souvent tue et vécue comme un tabou en France, Parce que le parcours du combat des personnes infertiles pour devenir parents n’est pas visible de celles et ceux qui les côtoient sur leurs lieux de travail, en famille, parmi leurs amis, Parce qu’être parent autrement aujourd’hui en France est un choix mûrement réfléchi et respectueux des droits des enfants à venir, Parce que la maladie reproductive est une réalité qui touche aujourd’hui 1 personne sur 6 en France et en Europe, MAIA et FAMILI se mobilisent pour organiser la 1ère Journée Nationale de l’infertilité qui réunit et fait se rencontrer familles, patient(e)s, spécialistes médicaux, thérapeutes, psychologues et associations du secteur. Plusieurs tables rondes seront organisées en présence de médecins et professeurs de renoms tels que le Professeur François Olivennes de la Muette, le Professeur Israël Nisand du CHU Strasbourg, le Professeur Renato Fanchin et la Professeur Célia Ravel du CECOS de Rennes. À leurs côtés, seront également présents de nombreux professionnels de la santé des hôpitaux Antoine-Béclère, La Muette, Bichat, Jean-Verdier, Sèvres, CHU Strasbourg, Cochin, Poissy, Trousseau, Bondy, de l’hôpital Américain et de la maternité des Diaconnesses (voir notre programme détaillé). Déborah Schouhmann-Antonio, initiatrice de cette journée, thérapeute en périnatalité et bénévole de l’association MAIA en responsable de l’antenne de Paris, et les sociologues Irène Théry, Dominique Mehl, seront également amenées à intervenir. Plusieurs associations apporteront leur soutien à cet événement : Association Maia, les Cigognes de l’espoir, Association Syndrome de Rokitansky-MRKH, Association ELHE Lilli H contre l’endométriose, Les filles DES. Seront abordés tout au long de la journée : chiffres de l’infertilité, quand et comment accéder à la PMA, les différentes techniques, effets secondaires et complications, maladies, aspects psychologiques et accompagnement, chances de succès. Des zooms particuliers également sur : être parent autrement, l’infertilité masculine, le couple face à l’infertilité et être mère après 40 ans. Parce que plus d’un million de personnes sont infertiles en France, MAIA et FAMILI unissent leur force le 23 mai prochain, pour faire entendre leurs voix, les informer, les soutenir et les accompagner dans leur désir d’être parent. MAIA, vous soutenir dans votre désir d’être parent. Contacts: firstname.lastname@example.org – email@example.com – firstname.lastname@example.org Téléphones : 06.14.28.58.62 – 06.28.56.46.66 – 06 60 72.89.09 ”
Few people are aware of Animal Pharma, the animal drug divisions within drug companies
American livestock is pumped full of harmful drugs, making our food dangerous and cruel at the same time.
” Most people are aware of Big Pharma, thanks to its advertising, but few are aware of Animal Pharma, the animal drug divisions within drug companies that sell livestock drugs by the ton. Unlike people Pharma, many Animal Pharma drugs do not require a prescription or a veterinarian and the hormones, growth promoters, feed additives and antiparasite and antifungal drugs are loosely regulated and monitored. The USDA tests for residues from the drugs in meat, poultry and egg products but repeat offender farms that release animals with violative drug residues into the human food supply are identified weekly. ”
The unthinking development and tragic use of diethylstilbestrol from 1941 to 1971 – without the freshness, clarity, or applicability of DES: The Complete Story (1981), by Cynthia Orenberg, a medical writer and a victim. Robert Meyers begins with the drug’s synthesis in England, and follows its popularization and marketing, there and in the US, as a treatment for threatened miscarriage – to the point that it was prescribed for women with no symptoms or history of miscarriage. (Some of those treated, in fact, were pregnant for the first time.) The beginning of the end came in 1971 with the first published report linking DES to cancer in the female offspring of women who had taken the drug. The frenetic outcome included lawsuits by patients, FDA foot-dragging, and catastrophic medical treatment – elements which Meyers is unable either to disentangle or weave together coherently. In his view, this twisted tale “is preeminently a story of people – the women who took it” and their families; all the other aspects – political, economic, medical – are “really elements that enter the funnel of American health care and come out on the doorsteps of American consumers.” And, rather than give the doctors’ role a hard going-over, Meyers takes a few tired pot-shots. (when a physician-interviewee puts on a white coat: “What was there about wearing that white coat? Did he speak better wearing the coat? With more authority?”) For rigor as well as personal involvement, Orenberg is far superior. Sources: KirkusReviews.com
Low Libido? Everyone’s heard of medication that can improve your sex life (hello, Viagra!), but some drugs can actually quash it.
If you’re feeling less than interested in having sex, the culprit might be in your medicine cabinet.
These products and additives add layers upon layers of toxins to your body as well as release carcinogens into the air you breathe. By limiting what you bring into your home, you are taking the first step in cancer prevention.
The stage of cellular differentiation at the time of DES exposure may be critical in the final expression of these abnormalities
The association of intrauterine exposure to diethylstilbestrol (DES) and the subsequent development of reproductive tract abnormalities in young women has been well documented. Although the incidence of vaginal adenocarcinoma was low in the exposed population, vaginal adenosis, a nonmalignant abnormality, was quite common. In order to study the pathogenesis of adenocarcinoma and to determine the frequency of adenosis following prenatal exposure to DES, timed pregnant CD-1 mice were treated s.c. with DES (dose range, 5 to 100 micrograms/kg/day) on Days 9 though 16 of gestation. This period corresponds to major organogenesis of the reproductive tract in the mouse. Female offspring were sacrificed between 1 and 18 months of age. In addition to nonmalignant abnormalities, some of which have been described in women exposed prenatally to DES, two cases of vaginal adenocarcinoma (2%) were observed in 91 prenatally DES-treated animals. No comparable epithelial lesions were seen in 158 control female mice. One other case of adenocarcinoma of the vagina was reported previously by this laboratory using the prenatally exposed animal model. In another series of mice treated prenatally with DES, 100 micrograms/kg/day, 3 of 20 (15%) 1-month-old animals and one of 10 (10%) 18-month-old treated offspring had glandular epithelium abnormally located in the vaginal fornices (adenosis). Other cervicovaginal abnormalities observed after prenatal DES exposure included structural alterations, cervical enlargement, squamous metaplasia in the endocervical canal, excess keratinization of the ectocervix and vagina, transverse folds and basal cell hyperplasia in the upper vagina, and prominent Wolffian duct remnants. Thus, vaginal adenosis in the mouse does not appear to be a common abnormality following treatment with DES in utero. Neonatal exposure to DES on Days 1 to 5, on the other hand, resulted in six of eight (75%) animals with adenosis at 35 days of age. Since perinatal mouse studies have reported high incidences of vaginal adenosis, but, to our knowledge, no cases of vaginal adenocarcinoma, the results presented in this report suggest that the stage of cellular differentiation at the time of DES exposure may be critical in the final expression of these abnormalities.